Latest news and press releases about Fate Therapeutics, Inc. (FATE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Price
| Price | $2.44 |
| Market Cap | $284M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | -2.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -65.08% |
| Return on Invested Capital | -57.47% |
| Return on Assets | -48.44% |
| Gross Margin | -343.01% |
| Operating Margin | -2058.08% |
| Net Margin | -1941.09% |
Related companies: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of FATE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks